JP2001526211A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001526211A5 JP2001526211A5 JP2000525083A JP2000525083A JP2001526211A5 JP 2001526211 A5 JP2001526211 A5 JP 2001526211A5 JP 2000525083 A JP2000525083 A JP 2000525083A JP 2000525083 A JP2000525083 A JP 2000525083A JP 2001526211 A5 JP2001526211 A5 JP 2001526211A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- form according
- core material
- hydrophilic
- atpase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 description 21
- 229940121819 ATPase inhibitor Drugs 0.000 description 11
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 11
- 239000011162 core material Substances 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 150000001447 alkali salts Chemical group 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 229960000381 omeprazole Drugs 0.000 description 5
- 238000013265 extended release Methods 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical group 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000009858 acid secretion Effects 0.000 description 2
- DNEHKUCSURWDGO-UHFFFAOYSA-N aluminum sodium Chemical compound [Na].[Al] DNEHKUCSURWDGO-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 159000000003 magnesium salts Chemical group 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 description 2
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000896 Ethulose Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000002071 phenylalkoxy group Chemical group 0.000 description 1
- -1 piperidino, morpholino Chemical group 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000004950 trifluoroalkyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9704869A SE9704869D0 (sv) | 1997-12-22 | 1997-12-22 | New pharmaceutical formulaton II |
| SE9704869-8 | 1997-12-22 | ||
| PCT/SE1998/002368 WO1999032091A1 (en) | 1997-12-22 | 1998-12-17 | Oral pharmaceutical extended release dosage form |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001526211A JP2001526211A (ja) | 2001-12-18 |
| JP2001526211A5 true JP2001526211A5 (https=) | 2006-02-16 |
| JP4865945B2 JP4865945B2 (ja) | 2012-02-01 |
Family
ID=20409571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000525083A Expired - Fee Related JP4865945B2 (ja) | 1997-12-22 | 1998-12-17 | 経口の延長放出性医薬品剤形 |
Country Status (38)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207198B1 (en) * | 1995-09-21 | 2001-03-27 | Schwarz Pharma Ag | Composition containing an acid-labile omeprazole and process for its preparation |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| ATE500815T1 (de) | 1997-12-08 | 2011-03-15 | Dietrich Rango | Neue suppositoriumsform mit säureempfindlichem wirkstoff |
| FR2774288B1 (fr) * | 1998-01-30 | 2001-09-07 | Ethypharm Sa | Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques |
| ZA9810765B (en) * | 1998-05-28 | 1999-08-06 | Ranbaxy Lab Ltd | Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole. |
| FR2793688B1 (fr) | 1999-05-21 | 2003-06-13 | Ethypharm Lab Prod Ethiques | Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques |
| US7029701B2 (en) * | 2000-09-11 | 2006-04-18 | Andrx Pharmaceuticals, Llc | Composition for the treatment and prevention of ischemic events |
| WO2002032427A1 (en) * | 2000-10-20 | 2002-04-25 | Galephar M/F | Stable oral formulation containing benzimidazole derivative |
| KR20030072555A (ko) * | 2000-12-07 | 2003-09-15 | 알타나 파마 아게 | 산 불안정성 활성 성분을 포함하는 신속 붕해 정제 |
| JP4848101B2 (ja) * | 2001-08-17 | 2011-12-28 | 株式会社フジモト・コーポレーション | 徐放性マイクロペレット |
| CA2480826C (fr) | 2002-04-09 | 2012-02-07 | Flamel Technologies | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s) |
| TW200410955A (en) | 2002-07-29 | 2004-07-01 | Altana Pharma Ag | Novel salt of (S)-PANTOPRAZOLE |
| EP1543840A4 (en) * | 2002-09-26 | 2006-03-01 | Astellas Pharma Inc | AGENTS FOR IMPROVING THE ABSORPTION OF PHARMACEUTICAL PRODUCTS |
| JP4493970B2 (ja) * | 2002-10-16 | 2010-06-30 | 武田薬品工業株式会社 | 持続性製剤 |
| EP2596791B1 (en) | 2002-10-16 | 2015-04-01 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
| MY148805A (en) * | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| JP4933033B2 (ja) * | 2003-03-17 | 2012-05-16 | 武田薬品工業株式会社 | 放出制御組成物 |
| US8980322B2 (en) | 2003-03-17 | 2015-03-17 | Takeda Pharmaceutical Company Limited | Controlled release composition |
| CL2004000983A1 (es) * | 2003-05-08 | 2005-03-04 | Altana Pharma Ag | Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y |
| PE20050150A1 (es) * | 2003-05-08 | 2005-03-22 | Altana Pharma Ag | Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo |
| WO2005012289A1 (en) * | 2003-07-17 | 2005-02-10 | Altana Pharma Ag | Novel salt of (r) - pantoprazole |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| TWI372066B (en) | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
| FR2861990B1 (fr) * | 2003-11-10 | 2006-02-10 | Nouveaux Produits Pharma | Comprimes faiblement doses a reseau de polymeres |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| CA2469427A1 (en) * | 2004-06-01 | 2005-12-01 | Pharmascience Inc. | Dry mixed dosage form containing benzimidazole derivatives |
| US8461187B2 (en) * | 2004-06-16 | 2013-06-11 | Takeda Pharmaceuticals U.S.A., Inc. | Multiple PPI dosage form |
| WO2006082523A2 (en) * | 2005-01-25 | 2006-08-10 | Aurobindo Pharma Limited | Pharmaceutical sustained release composition of metformin |
| KR100591142B1 (ko) * | 2005-11-04 | 2006-06-20 | 지엘팜텍 주식회사 | 파록세틴을 활성물질로 함유하는 장용성 서방형 정제 |
| DE102005060393A1 (de) * | 2005-12-16 | 2007-06-21 | Add Advanced Drug Delivery Technologies Ltd. | Orales Präparat mit kontrollierter Freisetzung |
| US20090175959A1 (en) * | 2005-12-28 | 2009-07-09 | Takeda Pharmaceutical Company Limited | Controlled Release Solid Preparation |
| AU2007266574A1 (en) * | 2006-06-01 | 2007-12-06 | Dexcel Pharma Technologies Ltd. | Multiple unit pharmaceutical formulation |
| WO2008094877A2 (en) * | 2007-01-30 | 2008-08-07 | Drugtech Corporation | Compositions for oral delivery of pharmaceuticals |
| US8679541B2 (en) * | 2007-03-14 | 2014-03-25 | Particle Dynamics International, Llc | Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals |
| SG185296A1 (en) * | 2007-10-12 | 2012-11-29 | Takeda Pharmaceuticals Usa Inc | Methods of treating gastrointestinal disorders independent of the intake of food |
| US12011423B2 (en) | 2007-11-06 | 2024-06-18 | Foraviset Ltd. | S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders |
| WO2010103365A2 (en) | 2009-03-09 | 2010-09-16 | Council Of Scientific & Industrial Research | Sustained release composition of therapeutic agent |
| US20140127296A1 (en) * | 2012-11-05 | 2014-05-08 | Kenneth John Tibbs | Pharmaceutical preparation and method for treatment of diabetes |
| ES2744406T3 (es) | 2013-02-13 | 2020-02-25 | Redhill Biopharma Ltd | Composiciones farmacéuticas para el tratamiento de helicobacter pylori |
| CN104721185A (zh) * | 2013-12-21 | 2015-06-24 | 辰欣药业股份有限公司 | 一种提高埃索美拉唑钠稳定性的方法 |
| WO2016174664A1 (en) | 2015-04-29 | 2016-11-03 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| WO2017145146A1 (en) | 2016-02-25 | 2017-08-31 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| US10729735B1 (en) | 2016-09-14 | 2020-08-04 | Phoenix Biotechnology, Inc. | Method and compostitions for treating coronavirus infection |
| US11878011B2 (en) | 2020-05-07 | 2024-01-23 | Redhill Biopharma Ltd. | Method for eradicating Helicobacter pylori infection in patients regardless of body mass index |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| SE8301182D0 (sv) * | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
| IL75400A (en) * | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| AU4640985A (en) * | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
| SE8601624D0 (sv) * | 1986-04-11 | 1986-04-11 | Haessle Ab | New pharmaceutical preparations |
| US5229181A (en) * | 1990-10-30 | 1993-07-20 | Amber Technologies | Tubular knit cleanroom wiper |
| TW209174B (https=) | 1991-04-19 | 1993-07-11 | Takeda Pharm Industry Co Ltd | |
| IT1251153B (it) | 1991-08-06 | 1995-05-04 | Vectorpharma Int | Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica |
| US5178867A (en) * | 1991-08-19 | 1993-01-12 | Alza Corporation | Dosage form for delivering drug in short-time period |
| JP3140465B2 (ja) * | 1992-09-18 | 2001-03-05 | 山之内製薬株式会社 | ハイドロゲル徐放性製剤 |
| JPH06199657A (ja) * | 1992-12-10 | 1994-07-19 | Sumitomo Pharmaceut Co Ltd | 徐放性製剤 |
| SE9301830D0 (sv) * | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| JPH07330629A (ja) * | 1994-06-02 | 1995-12-19 | Nippon Shokubai Co Ltd | 徐放性製剤 |
| CA2193681A1 (en) * | 1994-07-08 | 1996-01-25 | Astra Aktiebolag | New oral pharmaceutical formulation containing magnesium salt of omeprazole |
| EE03305B1 (et) * | 1994-07-08 | 2000-12-15 | Astra Aktiebolag | Paljuosaline tableteeritud annusvorm I |
| SE9500422D0 (sv) * | 1995-02-06 | 1995-02-06 | Astra Ab | New oral pharmaceutical dosage forms |
| US5945124A (en) * | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
| US6132768A (en) | 1995-07-05 | 2000-10-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors |
| SE9600071D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
| WO1997047285A1 (en) * | 1996-06-10 | 1997-12-18 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
| SE9602442D0 (sv) * | 1996-06-20 | 1996-06-20 | Astra Ab | Administration of pharmaceuticals |
| DE19626045C2 (de) * | 1996-06-28 | 1998-12-03 | Klinge Co Chem Pharm Fab | Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben |
| US7016717B2 (en) * | 2002-07-05 | 2006-03-21 | The Regents Of The University Of California | Near-infrared spectroscopic tissue imaging for medical applications |
| ITPD20050230A1 (it) * | 2005-07-28 | 2007-01-29 | Marcato Spa | Macchina ad uso domestico per la estrusione di paste alimentari fresche |
-
1997
- 1997-12-22 SE SE9704869A patent/SE9704869D0/xx unknown
-
1998
- 1998-12-08 ZA ZA9811239A patent/ZA9811239B/xx unknown
- 1998-12-09 AR ARP980106244A patent/AR017201A1/es not_active Application Discontinuation
- 1998-12-09 TW TW087120440A patent/TWI249410B/zh not_active IP Right Cessation
- 1998-12-11 MA MA25383A patent/MA26576A1/fr unknown
- 1998-12-16 DZ DZ980295A patent/DZ2685A1/xx active
- 1998-12-16 TN TNTNSN98229A patent/TNSN98229A1/fr unknown
- 1998-12-17 EE EEP200000383A patent/EE04901B1/xx not_active IP Right Cessation
- 1998-12-17 TR TR2000/01981T patent/TR200001981T2/xx unknown
- 1998-12-17 DK DK98964631T patent/DK1043976T3/da active
- 1998-12-17 CZ CZ20002314A patent/CZ299228B6/cs not_active IP Right Cessation
- 1998-12-17 SK SK807-2000A patent/SK284988B6/sk unknown
- 1998-12-17 RU RU2000116011/14A patent/RU2214232C2/ru not_active IP Right Cessation
- 1998-12-17 BR BR9814378-6A patent/BR9814378A/pt not_active Application Discontinuation
- 1998-12-17 PL PL98341428A patent/PL193776B1/pl unknown
- 1998-12-17 KR KR1020007006908A patent/KR100755154B1/ko not_active Expired - Fee Related
- 1998-12-17 HU HU0101437A patent/HUP0101437A3/hu unknown
- 1998-12-17 KR KR1020067016717A patent/KR20060097069A/ko not_active Withdrawn
- 1998-12-17 CA CA002315261A patent/CA2315261C/en not_active Expired - Fee Related
- 1998-12-17 DE DE69832816T patent/DE69832816T2/de not_active Expired - Lifetime
- 1998-12-17 US US09/555,744 patent/US6605303B1/en not_active Expired - Lifetime
- 1998-12-17 NZ NZ505127A patent/NZ505127A/xx unknown
- 1998-12-17 EP EP98964631A patent/EP1043976B1/en not_active Expired - Lifetime
- 1998-12-17 ES ES98964631T patent/ES2252875T3/es not_active Expired - Lifetime
- 1998-12-17 CN CNB988136163A patent/CN1171582C/zh not_active Expired - Fee Related
- 1998-12-17 IL IL13682798A patent/IL136827A0/xx not_active IP Right Cessation
- 1998-12-17 AT AT98964631T patent/ATE312602T1/de not_active IP Right Cessation
- 1998-12-17 UA UA2000063360A patent/UA69397C2/uk unknown
- 1998-12-17 HR HR20000380A patent/HRP20000380B1/xx not_active IP Right Cessation
- 1998-12-17 WO PCT/SE1998/002368 patent/WO1999032091A1/en not_active Ceased
- 1998-12-17 AU AU19912/99A patent/AU759634B2/en not_active Ceased
- 1998-12-17 JP JP2000525083A patent/JP4865945B2/ja not_active Expired - Fee Related
- 1998-12-17 YU YU36700A patent/YU36700A/sh unknown
- 1998-12-21 MY MYPI98005796A patent/MY126555A/en unknown
-
1999
- 1999-02-17 SA SA99191077A patent/SA99191077B1/ar unknown
-
2000
- 2000-06-08 IS IS5524A patent/IS5524A/is unknown
- 2000-06-15 IL IL136827A patent/IL136827A/en unknown
- 2000-06-21 NO NO20003218A patent/NO20003218L/no not_active Application Discontinuation
- 2000-07-17 BG BG104620A patent/BG65028B1/bg unknown
-
2006
- 2006-03-13 CY CY20061100346T patent/CY1106072T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001526211A5 (https=) | ||
| RU2000116011A (ru) | Пероральная фармацевтическая лекарственная форма с продолжительным высвобождением | |
| CA2315261C (en) | Oral pharmaceutical extended release dosage form | |
| US6610323B1 (en) | Oral pharmaceutical pulsed release dosage form | |
| KR100740218B1 (ko) | 벤즈이미다졸 유도체의 경구 투여용 약학적 제형 및 그제조방법 | |
| CN1236770C (zh) | 胃酸分泌抑制组合物 | |
| EP1607088B1 (en) | Controlled release composition | |
| RU96107040A (ru) | Многоединичный фармацевтический препарат, содержащий ингибитор протонного насоса | |
| CN1134668A (zh) | 含有质子泵抑制剂的多单元药物制剂 | |
| RU96120189A (ru) | Новые фармацевтические препараты и способы их получения | |
| JP2011157390A (ja) | 胃液において不溶性の微小顆粒、その調製方法、および薬学的調製物 | |
| JP2000512993A (ja) | Ｈ▲上＋▼，ｋ▲上＋▼−ａｔｐアーゼ阻害剤の投与計画 | |
| JP2002529497A (ja) | 改善された化学的方法および医薬処方物 | |
| EP3377046A1 (en) | Pharmaceutical composition containing a non-steroidal antiinflammatory drug and a proton pump inhibitor | |
| EA012261B1 (ru) | Лекарственные формы, содержащие ингибитор протонного насоса и прокинетический агент | |
| JP2014508187A (ja) | 選択的セロトニン再取り込み阻害薬の放出制御医薬組成物 | |
| EP1572098A2 (en) | Method of treating snoring and other obstructive breathing disorders | |
| CN1753674A (zh) | 泰妥拉唑在治疗胃食管反流性疾病中的应用 | |
| WO2006111853A2 (en) | Stable solid dosage forms of acid labile drug | |
| JP2005522462A (ja) | 気道疾患の治療のためのプロトンポンプ阻害剤の使用 | |
| CH699302A1 (de) | Orale pharmazeutische Formulierung für Omeprazol enthaltend eine spezifische Trennschicht. | |
| MXPA00005896A (en) | Oral pharmaceutical extended release dosage form | |
| HK1017991B (en) | Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid | |
| HK1017991A1 (en) | Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid |